| REDEFINE 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema / cagrilintide, Semaglutide Cardiovascular disease, Obesity / overweight | HbA1c 6.5-10% | Ph 3 | Active, not recruiting | 631 | Sep 2027 | — | |
| REIMAGINE 2A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 405 | Nov 2025 | — | |
| NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥35 | Ph 3 | Recruiting | 303 | Feb 2028 | — | |
| NCT05016882Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | CagriSema / cagrilintide, NNC0194-0499, Semaglutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 255 | Dec 2024 | — | |
| REDEFINE 1A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 254 | Oct 2024 | 2 | |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 196 | Mar 2026 | — | |
| REDEFINE 2A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 179 | Jan 2025 | 1 | |
| REIMAGINE 5A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Active, not recruiting | 163 | Jun 2026 | — | |
| NCT06131372A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | CagriSema / cagrilintide, Semaglutide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 128 | Sep 2025 | — | |
| NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Recruiting | 119 | Mar 2030 | — | |
| NCT07357766A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Not yet recruiting | 116 | Nov 2027 | — | |
| NCT06409130Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | CagriSema / cagrilintide, NNC0194-0499, Semaglutide Alcohol / substance use, MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 102 | Nov 2025 | — | |
| RENEW 2Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | CagriSema / cagrilintide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 67 | May 2027 | — | |
| NCT07357740A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-39.9 | Ph 2 | Not yet recruiting | 61 | Aug 2027 | — | |
| REIMAGINEYOUNGA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Not yet recruiting | 56 | Sep 2029 | — | |
| NCT06797869A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | CagriSema / cagrilintide, Semaglutide Diabetic neuropathy, Type 2 diabetes | BMI ≥25 | Ph 2 | Active, not recruiting | 54 | Aug 2026 | — | |
| NCT03856047Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | CagriSema / cagrilintide, Liraglutide Obesity / overweight | — | Ph 2 | Completed | 54 | Mar 2020 | 1 | results |
| REIMAGINE 3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 53 | Sep 2025 | — | |
| REIMAGINE 1A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | CagriSema / cagrilintide, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 50 | Oct 2025 | — | |
| NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 46 | Mar 2027 | — | |
| NCT06131437A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 46 | Dec 2025 | — | |
| RENEW 1Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | CagriSema / cagrilintide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 40 | May 2027 | — | |
| REDEFINE 6A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 37 | Jan 2025 | — | |
| NCT06780449A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 36 | Aug 2028 | — | |
| NCT05813925A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 28 | Jan 2025 | 1 | |
| NCT06388187A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Completed | 25 | Apr 2026 | — | |
| NCT04982575Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 23 | Jul 2022 | 1 | results |
| NCT07607587Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events | CagriSema / cagrilintide Obesity / overweight | — | Ph 1 | Not yet recruiting | 11 | Nov 2027 | — | |
| NCT05564104A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body | CagriSema / cagrilintide Healthy volunteers, Hepatic impairment | BMI 18.5-39.9 | Ph 1 | Completed | 4 | Sep 2024 | — | |
| NCT06719011A Study on How NNC0174-1213 Works in People With Overweight or Obesity. | CagriSema / cagrilintide Obesity / overweight | BMI 27-34.9 | Ph 1 | Recruiting | 2 | Mar 2026 | — | |
| NCT07184086A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 1 | Recruiting | 2 | Oct 2027 | — | |
| NCT04209049A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function | CagriSema / cagrilintide Healthy volunteers, Renal impairment | — | Ph 1 | Completed | 2 | Jan 2021 | — | |
| NCT04940078A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 2 | Jan 2022 | — | |
| RAMBOThe Role of the Amylin Analogue Cagrilintide in Bone Metabolism | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 1 | Recruiting | 1 | May 2028 | — | |
| NCT07411560A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | CagriSema / cagrilintide, GLP-1 / incretin class catch-all Obesity / overweight | Female | Ph 1 | Recruiting | 1 | Jan 2027 | — | |
| RASMUSUnderstanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 1 | Recruiting | 1 | Apr 2028 | — | |
| NCT07557953A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | CagriSema / cagrilintide Obesity / overweight | — | Ph 1 | Recruiting | 1 | Apr 2027 | — | |
| NCT07597018A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-34.9 | Ph 1 | Not yet recruiting | 1 | May 2027 | — | |
| NCT07605052A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight | CagriSema / cagrilintide Obesity / overweight | BMI 27-34.9 | Ph 1 | Not yet recruiting | 1 | Sep 2026 | — | |
| NCT02300844Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects | CagriSema / cagrilintide Healthy volunteers, Obesity / overweight | BMI 20-35 | Ph 1 | Completed | 1 | Mar 2016 | — | |
| NCT02958085Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight | CagriSema / cagrilintide Obesity / overweight | BMI 25-39.9 | Ph 1 | Completed | 1 | Jan 2018 | — | |
| NCT03600480A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 1 | Jun 2020 | 1 | |
| NCT03787225A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity | CagriSema / cagrilintide Healthy volunteers, Obesity / overweight | BMI 20-39.9 | Ph 1 | Completed | 1 | Jun 2019 | — | |
| NCT04074174Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant | CagriSema / cagrilintide Obesity / overweight | BMI 25-39.9 | Ph 1 | Completed | 1 | Mar 2020 | — | |
| NCT05254158A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity | CagriSema / cagrilintide Healthy volunteers, Obesity / overweight | BMI 20-39.9 | Ph 1 | Completed | 1 | Sep 2022 | — | |
| NCT05804162A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants | CagriSema / cagrilintide Healthy volunteers | BMI 23-29.9 | Ph 1 | Completed | 1 | Aug 2023 | 1 | |
| NCT06207877A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 1 | Oct 2024 | — | |
| NCT06267092A Study of How CagriSema Works on Appetite in People With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Healthy volunteers, Obesity / overweight | BMI 18.5-24.9 | Ph 1 | Completed | 1 | Apr 2025 | — | |
| NCT06289504A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 1 | Oct 2024 | — | |
| NCT06403761Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-45 · Established CVD | Ph 1 | Completed | 1 | Dec 2025 | — | |
| NCT06716307A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 1 | Mar 2025 | — | |
| NCT03617081First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men. | CagriSema / cagrilintide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 1 | Dec 2018 | — | |
